KURA News and Press, Kura Oncology Inc. From 09/01/22

SAN DIEGO, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Of...

Gainers: Beyond Meat ( BYND ) +6% . Grindrod Shipping Holdings  ( GRIN ) +5% . SpartanNash ( SPTN ) +5% . Cisco Systems ( CSCO ) +5% . Symbotic ( SYM ) +4% . Losers: Bed Bath & Beyond ( BBBY ) -19% . ...

Kura Oncology, Inc. (KURA) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Pete De Spain - Senior Vice President of Investor Relations Troy Wilson - President and Chief Executive Officer Tom Doyle - Senior Vice President of Finance...

Kura Oncology press release ( NASDAQ: KURA ): Q2 GAAP EPS of -$0.52 in-line. $450 million in cash, cash equivalents and investments provide runway through 2024 For further details see: Kura Oncology GAAP EPS of -$0.52 in-line

– Recommended Phase 2 dose for ziftomenib identified, pending FDA review – – Additional 18 patients enrolled in KOMET-001 trial of ziftomenib in NPM1-mutant and KMT2A-rearranged AML – – Preliminary activity observed in KURRENT-HN trial of tipifar...

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report second quarter 2022 financial results after ...

Kura's Phase 1b data for menin inhibitor Ziftomenib in treating NPM1 mutant and KMT2A rearranged acute myeloid leukemia, or AML, is expected this quarter. Prior data showed a complete remission in a NPM1 mutant AML patient who had failed 7 prior lines of treatment. The target mark...

Kura Oncology ( NASDAQ: KURA ) stock rises about 7% after Cantor Fitzgerald analyst Li Watsek initiated coverage with an Overweight rating and a price target of $30. The blockbuster potential of tipi combinations, and the potential of the next-generation FTI, KO-2...

Gainers: Avidity Biosciences ( RNA ) +7% . Tritium DCFC  ( DCFC ) +5% . Conduent ( CNDT ) +5% . Kura Oncology ( KURA ) +4% . Rent the Runway ( RENT ) +3% . Losers: AvePoint ( AVPT ) -5% . PriceSmart ( P...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...